Heidi Crayton, MD, and Maria Lopes, MD, discuss the most recent 2018 guidelines for multiple sclerosis treatment, emphasizing the need for updated guidelines, particularly in the payer space, to ...

A simple algorithm to aid in the selection of appropriate disease modifying therapies (DMTs) reduces racial disparities in patients with relapsing multiple sclerosis (MS), early new research showed.

A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will ...

LOS ANGELES — New guidelines on the use of disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS) provide updated guidance on starting, switching, and stopping treatment and ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

Advances in diagnostics and disease-modifying therapies have significantly expanded treatment options for MS over the past 2 ...

New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study published in ...